Economic burden of Parkinson's disease in Singapore

Eur J Neurol. 2011 Mar;18(3):519-26. doi: 10.1111/j.1468-1331.2010.03210.x. Epub 2010 Sep 14.

Abstract

Background: This study was carried out to evaluate the economic burden of Parkinson's disease (PD) and factors independently associated with individual components of total cost in Singapore.

Methods: A consecutive sample of 195 patients with PD (mean age: 68.2, men: 51.8%) attending a tertiary neuroscience clinic were identified and interviewed using standardized questionnaires including a financial burden questionnaire, two Health Related Quality of Life (HRQoL) questionnaires and the Beck Depression Inventory questionnaire.

Results: Annual total cost of PD from a societal perspective was SGD11345 (USD10129) per patient, with direct cost accounted for 38.5% and indirect cost 61.5%. The main cost components for direct medical cost, direct non-medical cost, and indirect cost was pharmacotherapy (50.4%), home care (76.1%), and productivity loss (97.9%), respectively. In multiple linear regression analysis, higher education, younger age and longer duration of PD were associated with higher total cost.

Conclusions: Parkinson's disease exerts a considerable burden on patients, health care system and society in Singapore. As productivity loss accounts for a large share of the economic burden imposed by PD, treatments and health care programmes with potential for returning patients to higher productivity are urgently needed.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cost of Illness*
  • Female
  • Health Care Costs
  • Health Services / economics
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / economics*
  • Quality of Life
  • Singapore